MnO2 modified hollow mesoporous silica nanoparticles for enhanced chemodynamic therapy

Chemodynamic therapy (CDT) exert its influence in tumor therapy by disrupting the redox equilibrium within tumor cells, inciting a cascade of oxidative stress reactions, and hamper the proliferation and survival of tumor cells. Harnessing the abundant expression of glutathione (GSH) at tumor sites, we devised a drug delivery system based on hollow mesoporous silica nanoparticles (HMSN), enveloped by an outer layer composed of MnO2. Upon exposure to GSH, MnO2 undergoes degradation into Mn2+, engaging in a Fenton reaction with the loaded dihydroartemisinin (DHA) within HMSN and intracellular H2O2. This intricate interplay results in the generation of reactive oxygen species (ROS). In vivo antitumor experiments showcased the significant efficacy of HMSN@DHA@MnO2 in restraining subcutaneous tumor growth in nude mice. Culminating in a striking tumor inhibition rate of 52.6%. The targeted methodology of this nanocarrier system holds substantial promise in advancing novel and efficacious strategies within the filed of tumor therapy.